I-Mab (“the Company,” NASDAQ: IMAB) is successfully listed on NASDAQ on January 17th, 2020. The pre-green shoe offering size is US$104 million and the post-green shoe offering size is US$119 million (“the Offering”). CICC acted as Joint Bookrunner in this IPO.

I-Mab is one of the first batch of Chinese companies listed in the U.S. in 2020, and the first Chinese biomed company listed on U.S. stock market in the recent two years. The shares initially offered under the International Offering have been significantly over-subscribed.

Company Overview
I-Mab is a dynamic, global biotech company exclusively focused on developing biologics of novel or highly differentiated in the therapeutic areas of immuno-oncology and autoimmune diseases. 

I-Mab's mission is to bring transformational medicines to patients through innovation. I-Mab's innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company's Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D and global partnerships. The Company is on track to become a fully integrated end-to-end global biopharmaceutical company with cutting-edge discovery platforms, proven preclinical and clinical development expertise, and world-class GMP manufacturing capabilities.

Before the Offering, I-Mab has raised over US$400 million in equity financing since its establishment in 2016, and the current shareholders of the Company include C-Bridge Capital, Tasly, Hony Capital, Hillhouse, Lake Bleu, CDH, Hopu and etc. The Company is headquartered in Shanghai and has offices in Beijing and the United States.

CICC’s Contributions
As one of the leading bookrunners of this IPO and the only bookrunner who has fully engaged in the project since 2018, CICC has participated in the formulation of the listing plan since the project began, and has taken the lead in solving key issues. Combining the rich executive experience with deep understanding of the Company and the industry, CICC has fully concluded the Company's investment highlights, carefully organized high-quality promotion and application materials, and won high recognition in the market. 

During the marketing period, through arranging multiple rounds of high-quality investor roadshows and providing investors with independent and objective professional analysis delivered by research analysts, CICC helped the Company successfully implement multiple high-quality investor orders before officially starting book-building, which laid a solid foundation for the listing and won high recognition from the management.

As a leading investment bank with “Chinese Roots, International Reach,” CICC will continue to utilize its capital market expertise as well as its seamless cooperation of onshore and offshore businesses to provide continuous support for our customers in terms of introduction of global investors, reaching international capital market, and promoting global business development.